solengepras
AssetAlso CVN-424, solangepras
GPR6 inverse agonist that modulates striatal motor pathways to reduce Parkinson’s motor fluctuations.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- GPR6
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Parkinson's disease
Phase 3, longevity.technology, 9 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.